

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 15, No. 18

October 7th, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- AMA RUC CPT Survey
- MPFS, ICD10, & MACRA Updates
- 4Q2016 Hematological Malignancies Updates
- 17th Multidisciplinary Management of Cancers: A Case-based Approach

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on October 21st. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The ANCO FAX News has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

In the next few weeks, ASCO in collaboration with multiple specialty societies will randomly distribute an *American Medical Association (AMA) Relative Value Scale Update Committee (RUC) survey of the following Current Procedural Terminology (CPT) codes*—hydration (96360, 96361), therapeutic (96372, 96374, 96375, 96377), and chemotherapy (96401, 96402, 96409, 96411). The survey will run from October 7th through October 21st. Learn more about the survey at asco1.sharefile.com/share?#/view/sda92cc3388d4f638.

ASCO, ACCC, and ASH have submitted comments on the proposed Medicare *Physician Fee Schedule for CY2017*—read ASCO's comments at www.asco.org/sites/new-www.asco.org/files/content-files/2017-MPFS-Comments.pdf; read ACCC's comments at www.accc-cancer.org/advocacy/pdf/2017-proposed-PFS-comments.pdf?_zs=bhddd1&_zl=uIdJ3; read ASH's comments at www.hematology.org/search.aspx?q=fee+schedule.

The 2017 ICD-10-CM and ICD-10-PCS code updates, including a complete list of code titles, are available online at www.cms.gov/Medicare/Coding/ICD10. In addition, CMS has published *Clarifying Questions and Answers Related to the July 6, 2015, CMS/AMA Joint Announcement and Guidance Regarding ICD-10 Flexibilities* that addresses some of the issues regarding the 12-month grace period or flexible implementation date ending in October 2016 (see page 8 of the document at www.cms.gov/Medicare/Coding/ICD10/Clarifying-Questions-and-Answers-Related-to-the-July-6-2015-CMS-AMA-Joint-Announcement.pdf). Physicians are reminded that as of October 1st ICD-10-CM codes to the correct degree of specificity will be

required in their submitted claims.

The Community Oncology Alliance (COA) recently testified before the House Committee on the Budget regarding CMS's proposed Medicare Part B experiment. After the hearing, several *Representatives* began circulating a letter to CMS that looks to rein in overreach by CMMI asking CMMI to stop experimenting with Americans' health and cease all mandatory demos. Additionally, they ask CMMI to ensure that future models comply with current law, including appropriate limitations on the size and scope of the models and not expanding models without *Congressional* approval. Read the letter at www.communityoncology.org/2016/09/20/september-20-reps-tom-price-paulsen-boustany-circulate-letter-to-cms/ and ask your *Representative* to sign it today at cqrccengage.com/asco/app/onestep-write-a-letter?0&engagementId=247773. This effort is in addition to asking *Representatives* to support HR5122 that would prevent CMS from moving forward with the Part B experiment.

CMS has announced that it will allow physicians to choose the level and pace at which they comply with the new MACRA Medicare payment reforms. Participating at any level in 2017 will ensure that you will not be hit with payment penalties in 2019. Under the MIPS fee-for-service program, the most lenient participation option would allow physicians to simply "test" the program to ensure that their systems are working and that they are prepared for broader implementation in 2018 and beyond. While physicians who choose this option will not receive bonus payments, they will avoid a negative penalty. Under the second option, physicians can opt to submit data for less than the full reporting year. While CMS has not yet specified the timeline, it is believed that the 2017 reporting period could be only 90-180 days. Physicians who choose this option would not only avoid a negative payment adjustment, but could receive a small bonus. The third option is to participate for the full calendar year. Under this option your practice could qualify for a modest positive payment adjustment. Finally, the fourth option is to participate in an advanced alternative payment model (APM) in 2017. If you receive enough of your Medicare payments or see enough of your Medicare patients through an APM in 2017, then you would qualify for a 5% incentive payment in 2019. Read CMS's announcement at blog.cms.gov/2016/09/08/qualitypaymentprogram-pickyourpace/ and ASH's

summary at www.hematology.org/Advocacy/Policy-News/2016/6688.aspx.

CMA, MOASC, and State Legislative & Regulatory Issues

The *American Medical Association* and *ReachMD* have produced a series of podcasts to provide physicians with an inside look at what's to come and what they can do now to prepare for the transition to MACRA. To listen to the podcasts, go to reachmd.com/programs/inside-medicare-new-payment-system/.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the *California Medical Association* (CMA).** While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you. The CMA's *Center for Economic Services* (CES) has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers.** For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

Forthcoming CMA webinars include:

- Assembly Bill 72: Out-of-Network Billing—How it Works, Who it Impacts, and How to Avoid It (October 19)
- Is Your Practice at Risk for a HIPAA Security Breach? (November 2)

Contact CMA's member help center at (800) 786-4262 or memberservice@cmanet.org for more information. Register online at www.cmanet.org/events.

***CMA Practice Resources* (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits,**

forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The October 2016 edition includes:

- Blue Shield to update fee schedule effective December 1
- Physicians encouraged to verify CHPI data by November 11
- Physicians must post nondiscrimination statements by October 16
- Know Your Rights: Managed care contractual protections
- The Coding Corner: How to apply CPT modifier 79

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—2015 PQRS Feedback Reports and 2015 Annual QRURs Available; New CERT Documentation Contractor Effective October 14; Medicare EHR Requirements for 2016 Participation; EHR Incentive Programs: 2016 Exclusions and Alternate Exclusions; Updated ICD-10 Flexibility FAQs and 2017 Codes; Evaluation and Management: Billing the Correct Level of Service; EHR Incentive Programs: Learn About Important Changes
- *Events*—2015 Supplemental QRUR Physician Feedback Program Call-October 20; How to Report Across 2016 Medicare Quality Programs Call-November 1
- *Publications*—SNF Quality Reporting Program Webcast: Audio Recording and Transcript-New; PQRS Call Addendum-New; Medicare Enrollment for Physicians and Other Part B Suppliers and Institutional Providers Fact Sheets-Revised; Medicare Part B Drug Average Sales Price Reporting by Manufacturers-Blending National Drug Codes MLN Matters Article-New; Medicare Parts A & B Appeals Process Booklet-Revised

- MolDX: CYP2B6 Test; FDA Approved ALK Companion Diagnostic Tests; FANCC Genetic Testing; CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response; —Billing and Coding Guidelines
- MolDX-CDD: Oncotype DX Breast Cancer for DCIS (Genomic Health) Draft LCD Published for Review and Comments
- Changes to Laboratory NCD Edit Software for January 2017 CR9806
- Stem Cell Transplantation for Multiple Myeloma, Myelofibrosis, and Sickle Cell Disease, and Myelodysplastic Syndromes-Second Revision CR9620
- Medicare Part B Drug ASP Reporting by Manufacturers-Blending National Drug Codes SE1623

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/workshops include:

- Getting Paid and Keeping It-In-Person Seminar (Union City, October 25)
- Evaluation and Management Modifiers (October 26)
- Ordered, Referred and Prescribed Services (November 15)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

***Noridian/JEMAC* will soon be deactivating billing privileges for physicians who received revalidation notices from *Noridian* but have not submitted completed applications to CMS.** To prevent deactivation, CMA recommends that practices look up their revalidation dates through the CMS look-up tool. If it shows that your practice missed the deadline, then you should submit and sign your application online immediately. Visit med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/provider-enrollment-revalidation-cycle-2 for more information.

Subscribe today to receive the DHCS/Medi-Cal Subscription Service (MCSS) via e-mail. The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go

to the MCSS Subscriber Form (files.medical.ca.gov/pubsdoco/mcss/mcss.asp) to subscribe.

A list of DHCS/MediCal webinars is at <https://learn.medical.ca.gov>.

UnitedHealthcare's Network Bulletin (October 2016) is now available online at unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles entitled *New National Drug Code (NDC) Requirement Policy and Communication Effectiveness Survey*.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2016 Hematological Malignancies Updates

ANCO is organizing a series of *Hematological Malignancies Updates* in 2016. The third *Update* will take place on November 12th at the *Stanford Park Hotel* with Bruno Medeiros, M.D., *Stanford University*, Jeffrey L. Wolf, M.D., *University of California, San Francisco*, and Gregory P. Kaufman, M.D., *Stanford University*. The latest research on novel treatment modalities for acute and chronic leukemias, and myeloma, along with case studies for these diagnoses were presented. The program begins at 8:30AM with breakfast. This meeting is supported by *Janssen Biotech*, *Seattle Genetics*, and *Takeda Oncology*. Space is limited to the first 50 physician or nurse registrants only. Meeting announcements were mailed in early-October. To register for this meeting, please send your name, affiliation, and e-mail address to execdir@anco-online.org (Subject: 4Q2016 Clinical Meeting) or download and FAX the registration form at www.anco-online.org/4Q2016HemeMalig.pdf.

SAVE THE DATE

17th Multidisciplinary Management of Cancers: A Case-based Approach

The *17th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 17-19th, 2017. The meeting is sponsored by the *University of California, San Francisco, Office of Continuing Medical Education* and the *Association of Northern California Oncologists* and presented in collaboration by the *Stanford Cancer Institute*,

UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center. Go to www.multicancers.org to receive registration, housing, and additional information about this meeting as it becomes available.

Additional Education Meetings

Other meetings of possible interest to ANCO

October 19th-21st

ACCC 33rd National Oncology Conference: The How-To Conference for the Cancer Care Team
Association of Community Cancer Centers

St. Louis

(www.accc-cancer.org/meetings/NOC2016.asp)

October 26th

Coping with the Stresses of Caregiving When Your Loved One Has Triple Negative Breast Cancer (Part II of Living with Triple Negative Breast Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 27th

Living with Metastatic Breast Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 30th-November 2nd

2016 Annual Conference

Medical Group Management Association
San Francisco

(www.mgma.com/annual-conference/why-attend)

November 1st

Advances in the Treatment of Lung Cancer (Part I of Living with Lung Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 2nd

Treatment Update on Pancreatic Cancer (Part I of Living with Pancreatic Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 3rd

Update on Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 7-9th

Novel Cancer Therapeutics Summit 2016

Global Technology Community

November 10th

Update on Neuroendocrine Tumors
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 15th

For Caregivers: Practical Tips for Coping with Your Loved One's Lung Cancer (Part II of Living with Lung Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 16th

For Caregivers: Coping with Your Loved One's Pancreatic Cancer (Part II of Living with Pancreatic Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 17th

Advances in Immunotherapy in the Treatment of Lymphoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 18th

Treatment Update on Soft Tissue Sarcoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

December 3rd-6th

58th ASH Annual Meeting & Exposition
American Society of Hematology

San Diego

(www.hematology.org/Annual-Meeting/)

December 12th

Update on Lymphoma from the 2016 American Society of Hematology (ASH) Annual Meeting

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

January 19th-21st

2017 Gastrointestinal Cancers Symposium: Multidisciplinary Precision Care—Progress and Innovation

American Society Clinical Oncology
San Francisco

(<http://gicasym.org>)

January 27-28th

Cancer Survivorship Symposium: Advancing Care and Research—A Primary Care and Oncology Collaboration

American Society Clinical Oncology
San Diego

(<http://survivorsym.org>)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

Annual Election

Four seats on the ANCO *Board of Directors* are up for election in 2016. ANCO seeks nominations for candidates for these seats. This year's election will be conducted via mail ballot in December. Candidates with the top four vote totals will serve for three years (i.e., from 2017-2019, inclusive). Nominate an ANCO member (including yourself) to stand for election to the *Board* via e-mail/FAX to the ANCO office at execdir@anco-online.org/(415) 472-3961 no later than November 18th.

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The next regularly scheduled ANCO *Board of Directors* teleconference is scheduled for October 18th. Please call José Luis González, ANCO *Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

Twelve distinguished ASCO members, including two ANCO members—Eric J. Small, M.D., *University of California, San Francisco*, and A. Dimitrios Colevas, M.D., *Stanford University*—have been selected by the ASCO *Nominating Committee* as candidates for open leadership positions within the *Society*. Biographical information and interviews with each candidate will be posted to asco.org/election on October 26th; the election will take place between November 1st and December 2nd.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Stanford's Hematology Review of the 58th Annual ASH Meeting takes place on February 4th in Half Moon Bay. For more information and to register, go to cme.stanford.edu/hematology.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

- *AbbVie* • *Alexion Pharmaceuticals* • *AMGEN*
- *ARIAD Pharmaceuticals* • *Astellas Oncology*
- *AstraZeneca* • *Bayer Healthcare Pharmaceuticals*
- *Boehringer Ingelheim Pharmaceuticals*
- *Bristol-Myers Squibb Oncology*
- *Cardinal Health Specialty Solutions*
- *Celgene* • *Clovis Oncology* • *Daiichi Sankyo*
- *Dendreon* • *Eisai* • *Exelixis*
- *Foundation Medicine*

Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pharmacyclics • Prometheus Laboratories, Inc.
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology

We especially wish to thank and welcome *AbbVie*, *ARIAD Pharmaceuticals*, *Clovis Oncology*, *Exelixis*, *GenPath Oncology*, *Guardant Health*, *Heron Therapeutics*, *Infinity Pharmaceuticals*, *Ipsen Pharmaceuticals*, *Jazz Pharmaceuticals*, *Merrimack Pharmaceuticals*, *Prometheus Laboratories, Inc.*, *Sandoz Biopharmaceuticals*, *Taiho Oncology*, and *Tesaro* as new Corporate Members for 2016. *Biosesix*, *Onyx Pharmaceuticals*, and *Sargas Pharmaceutical Adherence & Compliance (SPAC) International* did not renew their memberships for 2016. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AbbVie will host a clinical discussion entitled *Venclexta for Treatment of Previously Treated CLL with 17p Deletion* with Daruka Mahadevan, M.D., Ph.D., *University of Arizona Cancer Center*, on October 20th in Sacramento. Please RSVP by October 14th to Sean Traynor at (916) 521-7805 or go to abbvie.meintl.com/OHD08-OB02-16.

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved a blood-based companion diagnostic for Tagrisso to confirm the presence of a T790M mutation in patients with metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) medicine.

Genentech BioOncology informs ANCO that Tecentriq has been assigned a unique C code (C9483, 10mg).

Genentech BioOncology will host a dinner program entitled *Cotellic in Combination with Zelboraf for the Treatment of Unresectable or Metastatic Melanoma with BRAF V600E or V600K Mutation* with Scott Christensen, M.D., *University of California, Davis*, on October 12th in Modesto. Please RSVP by October 7th www.medforcereg.net/SGEN4602.

Novartis Oncology informs ANCO that the *United States Food and Drug Administration* has approved Arzerra for use in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).

Pharmacyclics will host an exhibitor theater to discuss *Imbruvica in CLL/SLL* with Keven R. Kelly, M.D., *University of Southern California*, on October 29th in Anaheim. Please RSVP at bit.ly/registerCSHP.

Clinical Trial News

DHHS has finalized a rule that expands and clarifies what clinical-trial data legally needs to be made public. Entities that perform clinical trials will face new rules designed to make sure that valuable information from patients is widely available, not only to the patients themselves but to scientists trying to advance medical science. The final rule goes into effect in January 2017. It clarifies that most interventional trials involving drugs, biological and device products need to be registered at ClinicalTrials.gov, and summary results for the studies need to be submitted within a year of a trial's completion. For more information, go to www.nih.gov/news-events/summary-hhs-nih-initiatives-enhance-availability-clinical-trial-information.

The Fall 2016 edition (as well as past editions) of *Stanford's Clinical Research Newsletter* is now available at cancer.stanford.edu/trials/mdcommunity_newsletter/. This edition focuses on the radiology, interventional radiology, radiation oncology, and developmental therapeutics programs

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- Randomized Phase II Study of Cisplatin and Etoposide vs Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas [ECOG-ACRIN-EA2142;

NCT02595424]. Principal Investigator: Pamela Kunz, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu

- PANAML: A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [PEDSHEM0006; NCT02676323]. Principal Investigator: Norman Lacayo, MD; Contact: Peds Hem/Onc CRAs, hemonccras@lists.stanford.edu
- A Phase 3 Randomized Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy [HEP0054; NCT02562755]. Principal Investigator: Nishita Kothary, MD; Contact: Risa Jiron, (650) 736-1598, hemonccras@lists.stanford.edu
- A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma [ECOG-ACRIN-S1404; NCT02506153]. Principal Investigator: Sunil Reddy, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu

UC Davis brings the following clinical trial (not previously listed or changed) to the attention of the ANCO membership:

- A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor (PHI-77/NCI#9898). Principal Investigator: Jonathan Riess, M.D.; Contact: Steffany Lim, (916) 734-0561

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- Phase 1 study to evaluate the safety of neratinib in combination with paclitaxel, trastuzumab, and pertuzumab in women and men with advanced or metastatic HER2+ solid tumors (NCI02593708). Contact: Kathleen Comerford, (415) 514-7433, kathleen.comerford@ucsf.edu
- A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons (NCT02437851). Contact: Rachel Silverstein, (415) 353-7443, rachel.silverstein@ucsf.edu
- A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma. Contact: Kelly Bauer, (415) 514-5633, kelly.bauer@ucsf.edu
- A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745

combined with Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma. Contact: Paige Steiding, (415) 514-6314, paige.steiding@ucsf.edu

- A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients (CC#16458). Contact: Paige Steiding, (415) 514-6314, paige.steiding@ucsf.edu
- A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma who Progressed on or Were Intolerant to First-Line Systemic Therapy (CC#16456). Contact: Kelly Bauer, (415) 514-5633, kelly.bauer@ucsf.edu
- A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors (AMC095). Contact: Iliaria Mastroserio, (415) 514-6245; iliana.mastroserio@ucsf.edu
- A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer (CC#16459). Contact: Paige Steiding, (415) 514-6314; paige.steiding@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

Free PQRS reporting is now available through ASCO's *Quality Oncology Practice Initiative* (QOPI). All users will be able to use the QOPI system to fulfill the Oncology Measures Group set of seven measures for PQRS reporting. Learn more at www.asco.org/advocacy-policy/asco-in-action/free-pqrs-reporting-now-available-through-qopi. QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the *QOPI Certification Program* to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality and are eligible to receive a discount of up to 10% on medical malpractice rates from *The Doctors Company*, the nation's largest physician-owned medical malpractice insurer. Go to www.instituteforquality.org/qopi-qcp for more information.

The September/October issue of ACCC's *Oncology Issues* includes articles entitled *Training Community Nurses & Administrators to Implement Cancer Clinical Trials*, *Delivering Pharmacogenetic Testing in the Community Setting*, and *Best of ASCO 2016*. Visit www.accc-cancer.org/oncology_issues to read this issue.

The *Community Oncology Alliance's* (COA) 2016 *Practice Impact Report* tracks the changing landscape of cancer care in the United States (www.communityoncology.org/2016-coa-practice-impact-report/). The latest edition reports a 121% increase in community cancer clinic closings and a 172% increase in consolidation with hospitals since 2008. California has the third largest number of community oncology practice closures (40).

NCCN has published and/or updated their *Clinical Practice Guidelines in Oncology* and/or *Drugs & Biologics Compendium* for acute lymphoblastic leukemia (V2.2016); chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (V1.2017); genetic/familial high-risk assessment: colorectal (V2.2016); kidney cancer (V1.2017); multiple myeloma (V1.2017); myelodysplastic syndromes (V1.2017); myeloproliferative neoplasms (MPN; V1.2017); occult primary (cancer of unknown primary [CUP], V1.2017); small cell lung cancer (V2.2017); vulvar cancer (V1.2017). Go to www.nccn.org for more information.